Vita 34 AG Reports Strong Q3 2024: 6.3% Revenue Growth and 77.5% EBITDA Increase

Vita 34 AG Reports Strong Financial Performance for Q3 2024

Vita 34 AG has released its financial results for the first nine months of 2024. The company noted a positive trend in revenue, profitability, and cash flow.

Key Financial Figures:

• Revenue: Increased by 6.3% to EUR 60.3 million, compared to EUR 56.7 million in the same period last year.
• EBITDA: Grew by 77.5% to EUR 6.4 million, aided by one-time effects from agreements with a US licensor.
• EBITDA Margin: Reached 10.6%, returning to a double-digit level.
• Operating Cash Flow: Rose by 61.1% to EUR 7.8 million.

Business Overview:
The company reported a strong performance in its end customer business (B2C), with service invoicing up by 12.4% to EUR 55.3 million. The annual recurring payments within this segment increased by 6.5%. The churn rate for customers remains below 1%, indicating stability in revenue generation.

Although overall business growth is encouraging, market conditions in key areas like Germany and Portugal remain challenging. Conversely, markets in Switzerland, Spain, Romania, and the GCC region showed positive growth.

Future Outlook:
Vita 34 plans to expand placenta tissue banking in Poland and Romania, following successful launches in Switzerland and the GCC. The company aims to rollout these services throughout Europe due to high demand.

The management maintains its revenue guidance for 2024 between EUR 81 million and EUR 88 million, with EBITDA expectations between EUR 6.5 million and EUR 8.0 million.

Company Background:
Founded in Leipzig in 1997, Vita 34 AG is the leading cell bank in Europe and the third largest globally. The company specializes in the collection, processing, and storage of stem cells from umbilical cord blood and other perinatal tissues. It serves customers in about 50 countries.

For more details, contact Vita 34 AG Investor Relations at ir@vita34.de.